ImpediMed (IPD) H2 2024 earnings summary

Executive summary

• FY24 total revenue declined 9% to $10.3 million, mainly due to the end of the AstraZeneca clinical trial, while SOZO Core Business revenue grew 14% to $9.7 million and annual recurring revenue (ARR) increased 18% to $11.0 million year-over-year.

• Patient tests rose 18% to 250,000, supporting device renewals and reflecting strong lymphedema prevention program engagement.

• The U.S. market generated 90% of core business revenue, with a strategic focus on expanding payer coverage and accelerating sales in high-reimbursement states.

• New executive and sales leadership drove improved lead generation, higher conversion rates, and a 20% reduction in sales lead time, with a refreshed commercial strategy and positive momentum in the U.S.

• Operating loss before tax narrowed to $19.8 million from $20.5 million in FY23.

Financial highlights

• SOZO Core Business ARR increased 18% year-over-year to $11.0 million, and Total Contract Value (TCV) rose 29% to $9.4 million.

• Gross margin improved to 87.3% from 86.4% in FY23.

• Operating cash outflow was $17.8 million, similar to the prior year.

• Cash balance at June 2024 was $24.6 million, down from $45.7 million in FY23.

• Other income rose by $1.2 million, driven by a non-recurring $1.9 million U.S. government grant.

Outlook and guidance

• Targeting free cash flow break-even by July 2025 through sales growth and strict cost management, with FY25 cash expenditure forecast to be 10% lower, mainly from headcount and salary adjustments.

• Focused on achieving 85% national payer coverage in the U.S. and expanding into new oncology indications.

• Continued execution of the commercial plan, product innovation, and 14 conferences scheduled to drive further pipeline growth.